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CD44 is a transmembrane glycoprotein and surface receptor 
for hyaluronan that is involved in the response of cells to their 
microenvironment. CD44 splice variants play roles in carcino-
genesis, differentiation, and lymph node metastasis and are 
predictive of the prognosis for various carcinomas, including 
gastric cancer. Current data suggest that gastric tissue stem 
cells and gastric cancer stem cells both express the splice 
variant, CD44v9. Overall, the data regarding the alterations 
that occur in CD44 and its splice variants in response to 
acute and chronic infection with Helicobacter pylori are scant 
and poorly elucidated in terms of possible changes in expres-
sion that occur in gastric cancer precursor lesions, such as 
chronic atrophic gastritis, pyloric metaplasia and intestinal 
metaplasia. In this study, we discuss the available data and 
suggest which new data would likely be useful in clinical 
practice. We also discuss the potential for CD44-targeted 
therapeutic strategies in gastric cancer. CD44 and its splice 
variants are positively associated with the initiation and pro-
gression of gastric cancer and may also play important roles 
in diagnosis, therapy and prognosis. CD44 research has 
been active but fragmented, and it may offer new therapeu-
tic approaches to gastric cancer. (Gut Liver 2011;5:397-405)
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INTRODUCTION
Gastric cancer is the one of the leading causes of cancer 
related deaths worldwide. Although the incidence of gastric 
cancer has been decreasing, it still represents roughly 2% of all 
new cancer cases yearly in the United States.
1-3 Approximately 
Correspondence to: Putao Cen
Department of Medical Oncology, University of Texas Health Science Center in Houston, 6410 Fannin, Suite 722, Houston, TX 77030, USA
Tel: +1-832-325-7702, Fax: +1-713-512-7140, E-mail: putao.cen@uth.tmc.edu
Received on August 16, 2011. Revised on September 18, 2011. Accepted on September 30, 2011.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2011.5.4.397
Current addresses: Byung Ik Jang: Yeungnam University College of Medicine, Daegu, South Korea; Yuan Li: Department of Gastroenterology, The 
Third Hospital of Peking University, Beijing, China.
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
90% of gastric cancers are adenocarcinomas which are divided 
into 2 types based on the degree of differentiation: the more 
common well differentiated intestinal-type and the less com-
mon poorly differentiated or diffuse-type.
4,5 The intestinal-type 
of gastric cancer has long been known to be tightly associated 
with atrophic gastritis and gastric atrophy.
6,7 The majority of 
gastric cancers are end products of an inflammatory cascade 
that progresses from superficial nonatrophic gastritis to gastric 
atrophy and is associated with the development of metaplastic 
epithelia, including the pyloric-type also known as spasmolytic 
polypeptide expressing, and the intestinal type, through intraep-
ithelial neoplasia (also known as dysplasia) to invasive cancer.
5 
This cascade is caused by infection with the bacterial pathogen 
Helicobacter pylori which is a necessary but not sufficient cause 
of gastric cancer.
Gastric cancer is not an inevitable outcome of a H. pylori 
infection, for example, the incidence of gastric cancer often var-
ies greatly between geographic regions despite their having an 
equally high prevalence of H. pylori infection. The pathogenesis 
of gastric cancer is complex and on a macro level is the result 
of interactions between bacteria, the host, and the environment. 
Factors associated with a more robust inflammatory response 
such as an infecting strain containing the cag pathogenicity 
island, or polymorphisms in host genes governing the response 
to inflammation, both increase the risk of gastric cancer for an 
individual patient. However, the most prominent factors sepa-
rating high and low risk populations are environmental and 
include diets high in salt, a low intake of fruits and vegetables, 
and smoking. 
Risk can also be stratified based on the severity and extent 
of atrophic gastritis which can be assessed endoscopically (e.g., 
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OLGA staging system), or biochemically based on serum pep-
sinogen assays.
7-9 Current data support the notion that gastric 
cancer related to H. pylori can largely be prevented if the infec-
tion is eradicated in the pre-atrophic stage. However, after the 
development of atrophic gastritis, H. pylori eradication can only 
reduce the risk of cancer but not completely prevent it.
10-13 
Overall, the prognosis of gastric cancer is poor with 5-year 
survivals below 24%.
1 However, endoscopic or surgical therapy 
of intraepithelial neoplasia or of early gastric cancers can result 
in cure or long survival such that surveillance for detection and 
removal of intraepithelial neoplasia and early gastric cancers 
are the main strategies to reduce the death rate from gastric 
cancer among high risk populations. Unfortunately, by the time 
stomach cancer causes symptoms, it is typically at an advanced 
stage with poor 5-year survival rates despite modern multimod-
al treatment strategies. Gastric cancer has also proven to not be 
particularly sensitive to current chemotherapy agents such that 
most therapy is palliative designed to reduce tumor size, relieve 
symptoms and increase survival time. Adjuvant chemotherapy 
to gastric cancer after surgery can modestly decrease distant re-
currence.
14 Novel biomarker to predict patient outcome and new 
therapies to achieve better tumor response are needed. CD44 
may play a role in this quest.
CD44 AND GASTRIC CANCER
CD44 is a principal cell surface receptor for hyaluronic acid, 
a major component of extracellular matrices. Originally de-
scribed as an antigen on red blood cells and platelets, CD44 was 
subsequently identified as a lymphocyte homing receptor.
15-17 
CD44 binds to hyaluronan and plays an important role in com-
munication of cell-matrix interactions into the cell via “outside-
in signaling.” CD44 is a transmembrane glycoprotein and 
along with the selectins, the integrins and the cadherins are cell 
adhesion molecules. CD44 has been reported to play important 
roles in adherence to the extracellular matrices, motility, matrix 
degradation, proliferation and cell survival.
18-20 Cell adhesion 
molecules control cell behavior by mediating contact between 
cells or between cells and the extracellular matrix which are 
essential for maintaining tissue integrity. These same functions 
are involved in pathological functions including tumor progres-
sion and metastasis which often involve dysregulation of cell 
adhesion molecules (i.e., loss of E-cadherin). 
CD44 is a family of glycoproteins encoded by a gene located 
on the short arm of human chromosome 11 (NG_008937).
21 The 
predominant form in epithelial cells is CD44s (standard) which 
consists of a link protein-homologous extracellular domains 
(exons 1-5 and 16), a transmembrane domain (exon 18) and 
a cytoplasmic domain (exon 20). CD44 isoforms arise by the 
alternative splicing of exons 6-15 and are designated as CD44v 
(variant). In theory, alternative splicing could allow more than 
100 different CD44 variants all of which are of increased size 
compared to CD44s. CD44s is widely distributed within the body 
whereas CD44 variants have a much more restricted distribution 
and are typically expressed on epithelial cells in a tissue specific 
pattern. Different CD44 isoforms may have different, often ad-
ditional, functions compared to CD44s. 
CD44 IN GASTRIC TISSUE, NORMAL, INFLAMED, ATRO-
PHIC, METAPLASIA, DYSPLASIA, CANCER, AND THE 
RELATION TO DIFFERENT VARIANTS
Data regarding CD44 expression in gastric tissue are confus-
ing in part because different investigators have used different 
techniques and approaches to investigate whether CD44 and/
or its splice variants are present in normal gastric tissue or are 
associated with various gastric pathologies. The data are further 
complicated by the fact many changes in gastric histology oc-
cur as a consequence of infection with H. pylori and these have 
not been systematically evaluated in terms of CD44 isoform ex-
pression. Normal gastric tissue composed of a complex mixture 
of cells divided into two major regions, the nonacid secreting 
antrum and the acid-secreting gastric corpus. Normal gastric 
mucosa is essentially devoid of inflammatory cells. H. pylori 
infection results in a robust inflammatory response consisting 
of both polymorphonuclear and mononuclear inflammatory 
cells as well as with progressive tissue damage and remodeling 
including the transformation to metaplastic epithelia. Both the 
inflammatory cell components and each of the different epithe-
lial cell components could theoretically express CD44s or one or 
more isoforms. In addition, published results with “normal” gas-
tric mucosa have generally not differentiated H. pylori infected 
from uninfected mucosa and authors have even gone so far as 
to use commercial gastric RNA as their reference material for 
normal stomach.
22
The primary techniques for investigating the presence and de-
gree of CD44 expression have been immunocytochemistry, fluo-
rescence cell sorting, and reverse transcript polymerase chain 
reactions (RT-PCR). Despite the availability of polyclonal and 
monoclonal antibodies to CD44s and the various isoforms, most 
studies have used broadly reactive antibodies which therefore 
provide limited information regarding whether the results refer 
to CD44s or one or more CD44v’s. Whenever possible, we will 
attempt to provide results in terms of CD44s and CD44 splice 
variants. When CD44s and CD44 isoforms were not differenti-
ated, we will refer to the results as CD44x. 
CD44 IN NORMAL STOMACH AND H. PYLORI INFECTION
Several studies have used immunological or RT-PCR to ex-
amine CD44 expression in “normal” stomach (Table 1).
22-26 Nor-
mal gastric epithelium strongly expresses CD44s with weak or 
absent expression of the various isoforms. As noted previously, 
normal may often include H. pylori infected mucosa. One study Jang BI, et al: CD44 and Gastric Cancer  399
that specifically examined H. pylori infected and uninfected 
stomachs
26 used nested RT-PCR to identify CD44 splice variants 
V2 to V10 in H. pylori infected and uninfected gastric mucosal 
biopsies and in relation to the presence of inflammation. How-
ever 71% of the H. pylori-negative biopsies showed chronic in-
flammation which was not further described and they may have 
been infected or have previously been infected. In addition, im-
munocytochemistry was not done to confirm protein expression 
or to localize the expression to a specific region of the stomach 
or cell type. With those caveats, they reported expression of 
CD44v8, v9, and v10 in approximately 40% of those with H. 
pylori gastritis, 15% to 20% of those with H. pylori-negative 
noninflamed gastric mucosa, and 18% to 24% of those with 
H. pylori-negative biopsies with chronic gastritis. RT-PCR for 
CD44v’s 2 to v7 were negative. They concluded that CD44v’s 8 
to 10 were expressed in both normal and H. pylori infected gas-
tric mucosa and that the presence of inflammation did not sig-
nificantly change expression. Fan et al.
25 used CD44s, CD44v6, 
and CD44v9 antibodies to study gastric epithelial cells and 
intraepithelial lymphocytes in H. pylori infected and uninfected 
individuals. Normal gastric epithelial cells and intraepithelial 
lymphocytes both expressed CD44s and CD44v6. Cd44v9 was 
not expressed on the gastric epithelium of H. pylori negative 
individual but was present in H. pylori infection (Table 1). Ex-
pression of CD44s on gastric epithelial cells but not on intraepi-
thelial lymphocytes was increased in the presence of H. pylori 
infection.
25 Yasui et al.
27 studied presumably H. pylori infected 
gastric mucosa with CD44v9 specific antibodies and reported 
expression of CD44v9 in the basolateral membranes of pyloric 
gland cells, in gastric adenomas, and in gastric carcinomas. H. 
pylori infection was also been reported to upgrade CD44x ex-
pression in the gastric epithelial cell line, AGS cells, but as this 
cell line was derived from a well differentiated gastric cancer 
and its response visa-a-via normal mucosa is unclear.
28
H. pylori infection has also been reported to increase the 
proportion with CD44v6 (i.e., in 63% of those with H. pylori 
infection vs 45% in those without).
29 In presumably H. pylori 
infected gastric mucosa, da Cunha et al.
22 reported very faint 
expression of CD44v6 localized to cells of the neck zone of the 
gastric glands and focally in deep glands of the gastric antrum.
CD44 IN GASTRIC CANCER
A significant stepwise increase in CD44v6 immunohisto-
chemical expression has been reported from normal gastric 
mucosal biopsies (rare and weak), intestinal metaplasia, gastric 
mucosa adjacent to but uninvolved with gastric carcinomas, 
intestinal metaplasia adjacent to the tumor, and the tumor itself 
causing the authors to suggest that CD44v6 expression is a late-
stage phenomenon in the progression from normal mucosa to 
gastric carcinoma.
30 da Cunha et al.
22 using fluorescent immu-
nocytochemistry confirmed that CD44v6 was rarely expressed 
in normal gastric mucosa but was increasingly expressed in 
gastric hyperplastic polyps, complete and incomplete intestinal 
metaplasia, and was overexpressed in low- and high-grade 
dysplasia and malignant lesions. They concluded CD44v6 is 
expressed de novo in premalignant, as well as in sporadic and 
hereditary malignant lesions of the stomach and suggested that 
the presence of CD44v6 was potentially a biomarker signaling 
early transformation of the gastric mucosa. 
The proportion of cases of diffuse vs intestinal type gas-
tric carcinoma expressing CD44v5 and/or CD44v6 varies 
among studies and no definitive statement can be made at this 
time.
22,27,30-43 Comprehensive studies taking into account differ-
ent isoforms, tumor histology, and prognosis will be needed to 
resolve this confusion. In brief, the expression of CD44v6 seems 
to correlate with the degree of tumor differentiation.
40 CD44v5 
expression has been related to advanced grade, lymph node me-
tastases.
44 Most signet ring carcinomas seem to express CD44v5 
whether evaluated in terms of RNA or protein expression 
whereas intestinal-type carcinomas often express both CD44v5 
and CD44v6.
42,44 Finally, a positive correlation has been de-
scribed between total CD44 and CD44v9 expression in primary 
tumors and tumor recurrence and mortality.
45
Intestinal metaplasia, a precancerous lesion, expresses 
CD44v5 and CD44v6 which is similar to the pattern in intesti-
nal-type tumors.
42 Heider et al.
42 suggested that the difference 
in CD44 variant expression between diffuse-type and intestinal-
type tumors by RT-PCR and immunochemistry would allow the 
two types to be discriminated on the basis of these molecular 
markers and that the expression of CD44v6 within precancer-
Table 1. CD44 Expression in the Normal Gastric Epithelium
CD44s CD44v6 CD44v7 CD44v8 CD44v9 CD44V9*I
Sneath, et al.
23,̈ +++ + + + ND +++
Higashikawa, et al.
24,̈  +++ + + + ND ND
da Cunha, et al.
22,̈ N D+N D N D N D N D
Fan, et al.
25,‡ +++ + ND ND +
̉ ND
da Cunha, et al.
22,§ +++ ND ND ND ND ND
Reihani-Sabet, et al.
26,§ ND ND ND Pos Pos ND
ND, not done.
*v9+v8 and or v7; 
̈Immunocytochemistry, 
̉Only expressed in H. pylori infectio; 
§RT-PCR.400  Gut and Liver, Vol. 5, No. 4, December 2011
ous tissue allowed it to be easily and rapidly distinguished from 
normal gastric mucosa. 
CD44 AND THE METASTATIC PROCESS
Günthert et al.
46 provided the first example of cell adhesion 
molecules playing a role in the metastatic process when they 
transfected plasmids expressing CD44s or CD44 isoforms into 
nonmetastatic rat pancreatic carcinoma cells and showed a 
significant relationship between CD44v6 expression and lymph 
node metastasis, lymphatic invasion, depth of invasion and tu-
mor stage. Their experiments prompted a host of studies inves-
tigating the possible role of CD44v6 in human cancer. In gastric 
cancer CD44v6 expression has also been implicated in the de-
velopment of lymph node metastasis, hematogenous metastasis, 
invasion and the pathological grade of the tumor (Tables 2 and 
3).
31,33-35,38-41,47 In one study of submucosal gastric carcinoma 
CD44v6 was found to be the only indicator of lymph node me-
tastasis.
39 In gastric micropapillary carcinoma CD44v6 expres-
sion was associated with a higher T classification, lymph node 
metastasis, and lymphovascular invasion. Detection of CD44v6 
mRNA in blood and bone marrow has also been reported to 
be sensitive and specific marker of micrometastasis.
38 In con-
trast, CD44v5 has been reported to be preferentially expressed 
in poorly differentiated type gastric cancer and in metastatic 
lymph nodes.
36,37
GASTRIC CANCER STEM CELLS CD44 VARIANTS
Cancer stem cells drive tumorigenesis and also give rise to 
the large population of differentiated progeny that make up 
the bulk of the tumor (i.e., they possess the ability to initiate 
tumor growth and sustain tumor self-renewal).
48,49 Cancer stem 
cells make up a small fraction of cell in leukemia and solid tu-
mors such as breast,
50 pancreas,
51 head and neck squamous cell 
carcinoma (HNSCC),
52 colon,
53 and prostate cancers.
54 In 2009, 
Takaishi et al.
55 used three gastric cancer cell lines with sizeable 
subpopulations of CD44 positive cells to identify gastric stem 
cells. They injected cells from these cell lines into the stomach 
and skin of severe combined immunodeficient (SCID) mice and 
found that only the CD44 positive cells showed tumorigenic 
ability and the stem cell properties of self renewal and differen-
tiation. SCID mice given CD44 positive cells developed tumors 
within 8 to 12 weeks and CD44 knockdown by short hairpin 











CD44 or CD44v positive cases/
Gastric adenocarcinoma 
cases (%)
CD44 or CD44v positive cases in 
different pathologic types (%)
Ghaffarzadehgan et al. 
  (2008)
33
CD44 Gastric mucosa Iran 0/100 (0) 65/100 (65)  IT 56/78 (72), DT 9/22 (41)
Kim et al. (2005)
47 CD44 Gastric mucosa Korea NA 142/729 (19) Cardia 46/165 (28) 
  noncardia 96/564 (17.0)
Liu et al. (2005)
40 CD44s Gastric mucosa China 3/22 (13.6) 19/40 (47.5)
CD44v6 Gastric mucosa China 0/22 (0) 25/40 (62.5)
Wang et al. (2006)
38 CD44v6 Blood China 0/14 (0) 39/46 (84.8) IT 9/14 (64.3), DT 30/32 (93.8)
CD44v6 Bone marrow China NA 40/46 (87.0)  IT 10/14 (71.4), DT 31/32 (96.9)
IT, intestinal-type cancer; DT, diffuse-type cancer.





Xin et al. (2001)
34   55 CD44v6 expression was positively correlated with advanced stage. Strong positivity was only 
detected in those with metastases. Patients with CD44v6 positive tumors revealed a lower 3- and 
5-year survival rate.
Joo et al. (2003)
41   99 CD44v6 showed significant relationships with lymphovascular invasion and TNM stage.
Liu et al. (2005)
40    62 The expression of CD44v6 was significantly associated with the lymph node metastasis, invasion 
and pathological grade of the tumor.
Chen et al. (2004)
35    43 The CD44v6 protein expression was significantly related to serosal infiltration, lymph node me-
tastasis, and TNM stage of disease.
Yamaguchi et al. (2002)
31 201 CD44v6(+) cancers were more frequently associated with hematogenous metastasis, the prognosis 
was significantly poorer in patients with CD44v6(+) tumors than in those with CD44v6(-) tumors.
Okayama et al. (2009)
39 135 CD44v6 was significantly associated with lymph node status.Jang BI, et al: CD44 and Gastric Cancer  401
RNA resulted in a decrease in tumorigenic ability.
55 Further-
more, CD44 positive gastric cell showed significant resistance 
to chemotherapy or radiotherapy. Authors used fluorescent 
cell sorting to separate CD44 positive and negative cells. Their 
antibody broadly reacted with all CD44 isoforms such that they 
were unable to address whether the effect was CD44v-specific.
55
CD44v9 appears to be the current most likely candidate stem 
cell marker. CD44v9 expression in the gastric mucosa was 
previously shown to be positively correlated with prolifera-
tive activity as assessed by Ki-67 expression
27 and, in addition, 
CD44v9 was found to be co-expressed with Ki-67. CD44v6 was 
also reported to be associated with expression of p53 but the 
expression was in different cells and in colorectal carcinoma, 
variant CD44 expression was found to precede p53 gene muta-
tion in the adenoma-carcinoma sequence.
56 One of the features 
of cancer stem cells is its resistance to chemotherapy, radio-
therapy and reactive oxygen stress. Recently, it has been shown 
that CD44v9 regulates redox status in gastric cancer cells which 
further links CD44v9 and gastric cancer stem cells.
57 Of interest, 
tissue stem cells are characteristically slow-cycling cells that 
are also Ki-67 negative. Recently, Ishimoto et al.
58 showed that 
what appeared to be gastric cancer stem cells in mice expressed 
CD44v9 (the antibody was to CD44V8-V10). Slow cycling and 
presumably tissue stem cells found in a normal squamocolum-
nar gland were also CD44v9 positive but were Ki-67 negative 
suggesting that tissue stem cells and gastric cancer stem cells 
may be able to be differentiated in terms of cycling (e.g., Ki-
67 expression or BrdU uptake). Whether differences exist in the 
associated CD44v9’s (e.g., amount of glycosylation, inclusion of 
additional genetic material such as intron 9, etc.) is unknown (see 
below).
CD44 AND RESPONSE TO CHEMOTHERAPY
Resistance of cancer to chemotherapy and radiotherapy, and 
recurrence of cancer is one attribute of cancer stem cells. CD44 
acts as a common downstream effector of RAS, and is con-
sidered a stem marker responsible for tumor progression and 
resistance to therapy.
59 Oxidative stress occurs when production 
of reactive oxygen species (ROS) exceeds the capacity of the 
cellular defense system consisting of redox enzymes and other 
antioxidant molecules. Like normal tissue stem cells, subsets of 
cancer stem cells in some tumors harbor low levels of ROS and 
manifest enhanced mechanisms for protection against reac-
tive oxygen species-mediated damage.
60 Recent studies suggest 
that CD44-mediated reactive oxygen species resistance is inde-
pendent of antioxidant gene expression and is the result of an 
interaction between CD44v9 and the cystine transporter subunit 
xCT which controls the intracellular levels of glutathione.
57 Can-
cer stem cells and normal stem cells possess an enhanced reac-
tive oxygen species defense system
60 suggesting that CD44v9 
may be important in stem cells of various tumor types.
57 The 
presence of CD44v9 in cancer stem cells also provides a ratio-
nale for CD44v-targeted therapy to impair reactive oxygen spe-
cies defense in cancer cells in order to sensitize them to current 
treatments.
CD44 GENE POLYMORPHISMS AS A MARKER FOR 
OUTCOME
The mortality associated with gastric carcinoma is almost 
entirely caused by metastatic disease such that the prognostic 
assessment relies mainly on TNM staging. However, wide indi-
vidual variability in prognosis is observed even within the same 
stage. Better prediction of metastatic potential of the primary 
tumor would assist in the management of patients with gastric 
carcinoma. Expression of CD44v9 has been correlated with 
the expression of Ki-67, development and the progression of 
the gastric carcinoma.
27 Recently, Winder et al.
61 reported that 
germline polymorphism in the CD44 gene, at least one G allele 
(GG; AG) at the CD44 +4883G>A gene locus (rs187116) as-
sociated with clinical outcome in patients with localized gastric 
adenocarcinoma. They found that patients having at least one G 
allele of CD44 rs187116 remained significantly associated with 
time to recurrence and overall survival and that patients harbor-
ing CD44 T-A haplotype were at the lowest risk of developing 
tumor recurrence and death. These results suggest that assess-
ment of CD44 polymorphisms may assist in identifying patients 
with localized gastric cancer who are at high risk for tumor 
recurrence.
ROLE OF CD44 IN CANCER THERAPY
Based on data from transgenic mice and humans, it appears 
that CD44v9 is expressed on both gastric tissue stem cells and 
gastric cancer stem cells. However, gastric cancer stem cells also 
co-express Ki-67 whereas tissue stem cells cycle slowly and 
frequently do not. Prior studies showed that CD44v9 was also 
co-expressed with Ki-67 in nonmetaplastic gastric mucosa not 
associated with gastric cancer. It seems likely that cells in “nor-
mal” gastric glands that co-express CD44v9 and Ki-67 may be 
daughter cells produced from gastric tissue stem cells and that 
CD44v9 is subsequently lost as the cells further differentiate into 
normal gastric epithelium. CD44v6 is expressed on differenti-
ated gastric cancer cells. The fact that different CD44 isotypes 
are expressed on gastric cancer stem cells and on differentiated 
gastric cancer glandular cells suggests a possible role for iso-
form specific anti-CD44 therapy. 
Methods to silence the CD44 gene include using a vector such 
as a lentiviral or pSico vector carrying a short hairpin RNA 
(shRNA) against CD44
55 or transfecting CD44 small interfering 
RNA (siRNA) in order to knockdown CD44.
62,63 However, cur-
rently these methods are primarily applicable to in vitro studies 
and their applicability to gastric cancer remains unclear. How-402  Gut and Liver, Vol. 5, No. 4, December 2011
ever, there has been considerable work in other systems. For ex-
ample, in an animal study, Misra et al.
64 intravenously injected 
pSico-CD44v6 shRNA plus a intestine-specific pFabpl promoter-
driven-Cre-recombinase plasmid packaged in transferring-
coated nanoparticles into a mouse model of intestinal adenoma 
and silenced CD44v6-v9mRNA expression, inhibited protein ex-
pression of CD44v6 variants (v6-9) and reduced tumor number 
with only a limited effect on CD44s-normal tissue.
CD44v interactions with hyaluronan are involved in the 
metastatic cascade. A number of methods to change CD44-
interactions have been developed including the use of small hy-
aluronan oligosaccharides, use of soluble CD44 to act as com-
petitive decoys for CD44, use of blocking antibody against the 
hyaluronan binding site, and finally inhibition of the post trans-
lational expression of CD44v with siRNA (reviewed in reference 
65) CD44 can internalize hyaluronan and thus is a target recep-
tor for hyaluronan-conjugated drugs, nanocarrier delivery sys-
tems, or for anti-CD44 antibodies linked to radioactive isotope 
or chemotherapeutic agents.
65 For example, an abioconjugate 
of hyaluronic acid with SN-38 chemotherapy has been used 
to target CD44 as the receptor for hyaluronan. This approach 
showed higher inhibitory activity on a gastric cancer cell line 
than exerted by unconjugated SN-38.
66 Hyaluronan-conjugated 
with cisplatin-loaded microparticles have been injected into 
peritoneum of mice with ovarian cancer producing increased 
uptake of cisplatin in the CD44 expressing cancer cells result-
ing in inhibition of tumor growth.
67 Liu et al.
68 used a liposomal 
nanovector to deliver miR34a, (microRNA-34a), a key negative 
regulator of CD44 in prostate cancer cells, in a mouse model 
of prostate cancer to inhibit tumor growth and metastasis and 
prolong survival. Bivatuzumab (BIWA4) a humanized mono-
clonal antibody against CD44v6 linked to radioisotopes for use 
in radiotherapy or to an antineoplastic drug for chemotherapy 
has been used in phase I trials in head and neck cancer show-
ing high tumor uptake along with sparing of normal tissue.
69-72 
Finally, an anti-CD44v6 antibody linked to the cytotoxic agent 
mertansine was used to stabilized the disease in patients with 
breast cancer refractory to conventional chemotherapy.
73
A challenge remains on how target antibodies to the specific 
CD44v uniquely expressed on the targeted cancer. As noted 
above, future research needs to be directed to identifying unique 
features within the CD44 gene and in the CD44 variants ex-
pressed so as to provide specificity to the regimen and allowed 
truly tailored treatment strategies. RT-PCR amplification and 
hybridization have shown that tumor cells exhibit a complex 
pattern of variant CD44 transcripts and that different CD44v 
patterns occur in different primary gastric tumors and in the 
lymph node metastasis derived from those tumors.
42 Studies will 
be needed to identify the relation between the target(s) of CD44 
antibodies and the data derived from studies using RT-PCR.
FUTURE RESEARCH
Understanding the roles of CD44 and its isoforms in the 
pathogenesis and treatment of gastric cancer would be en-
hanced by better understanding of the role and expression of 
CD44s and CD44 splice variants in H. pylori-infection, especial-
ly in relation to the various H. pylori-associated gastroduodenal 
pathologies. Not only is the current data scanty in terms of 
which isoform or isoforms are expressed but extends to the rela-
tion of their expression in different regions of the stomach and 
in the different immunological and epithelial cell types present. 
Information needed includes which isoforms are present, are 
the co-expressed on the same cell, what other important factors 
are co-expressed (e.g., Ki-67), and whether there are differences 
between what appears to be same isoform present on gastric 
tissue and gastric cancer stem cells (e.g., different glycosylation 
or different carbohydrate antigens, or genes such as intron 9, 
expressed). The reagents needed to obtain these data are cur-
rently available as are the tissue samples making collection of 
such data primarily a matter of priority rather than requiring 
overcoming technical problems.
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